Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this ...
Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...
Prurigo nodularis (PN) is extremely itchy skin that leads to a bumpy rash. The rash appears as the result of repeated scratching, picking, or rubbing of the itchy areas of the skin. There isn’t one ...
Please provide your email address to receive an email when new articles are posted on . Regulatory authorities in four countries have accepted nemolizumab filings indicated for prurigo nodularis and ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...
Please provide your email address to receive an email when new articles are posted on . The highest mean percentage change from baseline in itch scores occurred in the 30 mg group with a reduction of ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25 th World Congress of Dermatology (WCD) in Singapore. The results highlight ...
The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...
A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor. A review published in Dermatology and ...
The Food and Drug Administration has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication, according to a press release from the ...
Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in ...
About 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options. TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022/ PRNewswire/-- Regeneron Pharmaceuticals, Inc. and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results